73
Participants
Start Date
November 30, 2012
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
Recombinant human endostatin
Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles
cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles
laboratory biomarker analysis
CT perfusion imaging
Zhejiang Cancer Hospital, Hangzhou
Chinese Academy of Medical Sciences
OTHER
Fudan University
OTHER
Peking University Cancer Hospital & Institute
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER
Shandong Cancer Hospital and Institute
OTHER
Jiangsu Cancer Institute & Hospital
OTHER
Fujian Cancer Hospital
OTHER_GOV
The First People's Hospital of Lianyungang
OTHER
Zhejiang Cancer Hospital
OTHER